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a
A
*
*
1
T
E
R
1
2
3
4
5
6
7
8
9
R
T
e
m
r
C
z
a
e
O
t
i
dspirin for Prevention of
yocardial Infarction and Stroke
s the Right Dose 81 or 160 Mg/Day?
he recent Expert Consensus Document on Reducing the Gas-
rointestinal Risks of Antiplatelet Therapy and NSAID Use (1)
ecommends that the appropriate dose of aspirin (ASA) for
ardioprophylaxis is 81 mg/day. Many of the 50 million Americans
ho take ASA for cardioprophylaxis have been advised to take
arger doses: 160 or 325 mg/day. Should they be advised to
ecrease their dose to 81 mg/day?
I believe that this document (1) underestimates the impact of
he dosage of ASA on its ability to prevent myocardial infarction
MI) and stroke.
There is considerable evidence from 4 primary prevention trials
hat doses 160 mg/day may fail to prevent MI and stroke. ASA,
0 mg/day, failed to prevent MI in the Women’s Health Study (2),
5 mg/day failed to prevent MI in women in the HOT (Hyper-
ension Optimal Treatment) study (3), and 100 mg/day failed to
revent MI in men or women in the Primary Prevention Project
4). The findings were similar for the primary prevention of stroke
n these randomized trials. With the exception of the Women’s
ealth Study (2), which reported a 17% reduction in stroke (p 
.04), stroke was not decreased in the HOT study (3) or the
rimary Prevention Project (4). In a primary prevention trial in
atients with type 2 diabetes, Ogawa et al. (5) reported that ASA
1 or 100 mg/day did not decrease the incidence of stroke or MI.
I also believe that this document overestimates the impact of the
osage of ASA on the incidence of its major complication: upper
astrointestinal (UGI) bleeding. Their recommendation is based,
n part, on a paper by Weil et al. (6) that reported that the odds
atio (OR) of UGI bleeding in elderly patients with daily doses of
SA of 75, 150, and 300 mg/day were 2.3, 3.2, and 3.9,
espectively. This study (6) involved only 144 patients with UGI
leeding. Only 27 patients took ASA 75 mg/day, and 22 took 150
g/day. Given the wide confidence intervals in this small study,
he differences in the ORs of UGI bleeding in the dose range of 75
o 300 mg/day were not significantly different.
In another report that they cited, Sorensen et al. (7) reported the
ndings in 27,694 ASA users who were hospitalized for UGI
leeding. The OR of UGI bleeding in 6,084 patients taking ASA
00 mg/day was exactly the same as the OR in the 22,671 patients
aking 150 mg/day. In a meta-analysis by Serebruany et al. (8) of
he bleeding complications in 50 randomized controlled trials of
SA therapy in 338,191 patients, the incidence of major bleeding
as the same in 13,337 taking 100 mg/day as in 43,489 patients
aking 100 to 325 mg/day (1.7%).
There is no evidence that the risk of UGI bleeding is increased
n patients who take ASA 160 mg/day compared with those who
ake 81 mg/day. There is considerable evidence that ASA doses160 mg/day are less effective in the primary prevention of strokend MI. Until contrary data emerge, I will continue to recommend
SA 160 mg/day for the primary prevention of MI and stroke (9).
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eply
he ACCF welcomes letters to inform its ongoing work and
ncourages such correspondence about its clinical policy state-
ents. Because the ACCF document development process is
igorous and involves several layers of review by the Writing
ommittee, external peer reviewers, and participating organi-
ations in the document, it cannot respond to each issue raised
fter a document has been published. The information, how-
ver, is forwarded to the Writing Committee Co-Chairs and
versight Task Force for review. If any issues are deemed by
he College to affect patient safety, they will be considered
mmediately. Otherwise, the information will be considered
uring the next revision of the document.doi:10.1016/j.jacc.2009.03.007
